Chondrocyte disc regeneration therapy - Isto Biologics

Drug Profile

Chondrocyte disc regeneration therapy - Isto Biologics

Alternative Names: Allogenic juvenile chondrocytes; NuQu; NuQu® Spine

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator ISTO Technologies
  • Developer Isto Biologics
  • Class Analgesics; Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Intervertebral disc degeneration

Most Recent Events

  • 01 Sep 2016 ISTO Technologies terminates a phase II trial in Intervertebral-disc-degeneration in USA (Parenteral) due to change in clinical strategy (NCT01771471)
  • 09 Feb 2016 Phase-II development is ongoing in USA
  • 07 Oct 2013 ISTO Technologies completes enrolment in its phase II trial for Intervertebral-disc-degeneration in USA (NCT01771471,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top